BIO praised Energy and Commerce Committee for approving 21st Century Cures Act. Commending said legislation for prioritizing placement of patients at center of drug development process, BIO President and CEO Jim Greenwood expressed support for establishing framework for incorporating patient views into development and regulatory review processes, focusing on precision medicine through genomics and regulatory science, modernization of clinical trials, and enhancing FDA's scientific capacity.